Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. Provided by PR Newswire Apr 29, 2025, 4:32:00 PM.

- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

Abeona Therapeutics enters Q2 2025 as a commercial-stage company with ZEVASKYN FDA approval, first patient site activation, and a $155 million PRV sale supporting a cash runway toward projected ...

ZEVASKYN is the first FDA-approved autologous cell-based gene therapy for treating wounds associated with RDEB, a severe skin disease that causes large, painful wounds and a high risk of cancer.

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

TUESDAY, April 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive ...

EB Research Partnership ("EBRP") invested in the work that led to ZEVASKYN at Stanford University under their pioneering Venture Philanthropy Model. This approval marks a historic moment for the EB ...